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SUMMARY 
A 74-year old man, with inflammatory arthritis recently commenced on adalimumab, presented 
with a four-week history of left-sided chest pain, malaise and shortness of breath. Admission 
electrocardiogram showed age-indeterminate left bundle branch block.  Troponin-T was 4444 
ng/L (normal range <15 ng/L) and acute coronary syndrome treatment was commenced. 
Catheter angiogram revealed mild-burden non-obstructive coronary disease. Cardiac magnetic 
resonance (CMR) was performed to refine the differential diagnosis and demonstrated no 
myocardial oedema or late gadolinium enhancement (LGE). Extra-cardiac review highlighted 
oedema and enhancement of the left shoulder girdle muscles consistent with acute myositis. 
Creatinine kinase was subsequently measured and significantly elevated at 7386 IU/L (normal 
range 30 – 200 IU/L in men). Electrophoresis clarified this was of predominantly skeletal muscle 
origin. Myositis protocol MRI revealed florid skeletal muscle oedema. The MR findings, together 
with positive anti-Scl-70 antibodies, suggested fulminant immune-mediated necrotizing 
myopathy (IMNM) presenting as a rare mimic of myocardial infarction with nonobstructive 
coronary arteries (MINOCA), diagnosed by careful extracardiac CMR review.  
 
BACKGROUND 
The idiopathic inflammatory myopathies (IIM) encompass a heterogeneous group of multisystem 
disorders characterised by inflammation (muscle, skin and joints), vasculopathy and fibrosis. 
Cardiac involvement in IIM is rare but potentially life-threatening. The term MINOCA is applied to 
patients with a clinical diagnosis of myocardial infarction and no evidence of obstructive 
coronary artery disease on angiography. The prevalence of MINOCA has been estimated at 
approximately 6%.[1] It is a distinct clinical entity, which requires further investigation in order to 
find the cause of each patient’s presentation so that targeted treatment can be instigated.[2] 
 
We report a case of IMNM in which cardiac magnetic resonance (CMR), autoimmune serology 
and careful analysis of serum biochemistry were instrumental in making the diagnosis that was 
masquerading as MINOCA.  
 
CASE PRESENTATION 
A 74-year-old man presented with four-week history of general malaise with chest pain, 
shortness of breath and peripheral oedema. Past medical history included inflammatory arthritis 
that had recently been treated with adalimumab.  The admission electrocardiogram (Figure 1) 
demonstrated age-indeterminate left bundle branch block, with QRS interval 140ms. troponin-T 
was elevated (4444 ng/L, normal range <15ng/L) in the context of serum creatinine of 91 μmol/L 
and an eGFR of 71 ml/min/1.73m2. 
 
INVESTIGATIONS  
A presumptive diagnosis of acute coronary syndrome was made and usual treatment 
commenced alongside intravenous diuretics. However, an urgent coronary angiogram 
demonstrated no obstructive coronary artery disease (Figure 2). His echocardiogram 
demonstrated good biventricular function, abnormal septal motion consistent with LBBB and no 
significant valve abnormality. The diagnosis was revised to MINOCA and a CMR study performed 
to distinguish a spontaneously re-canalised myocardial infarction (MI) from acute myocarditis. 
 
The CMR protocol included oedema-sensitive (T2-STIR) and late gadolinium enhancement (LGE) 
sequences. The CMR confirmed normal biventricular volumes and ejection fractions. There was 
dis-coordinated right ventricular contraction with a septal regional wall motion abnormality 
consistent with the known LBBB. A small pericardial effusion was demonstrated. No convincing 
myocardial oedema (Figure 3a, 3b 3c) or late gadolinium enhancement (Figure 3e, 3f, 3g) was 
present, suggesting recent/prior MI and/or myocarditis was unlikely. However, extra-cardiac 
review, demonstrated high signal return on STIR from the visualised left shoulder girdle muscles 
(Figure 3d) and some patchy enhancement on LGE in these appendicular muscles, in keeping 
with shoulder girdle myositis. The initial creatinine kinase (CK) was significantly elevated at 7386 
IU/L (normal range 30 – 200 IU/L in men). Subsequent CK electrophoresis, to differentiate 
between the various isoforms, indicated the elevated CK was predominantly of skeletal muscle 
origin with CK-MM contributing 89.2%, CK-MB 6%, and macro-CK type 1 (4.8%). No CK-BB was 
detected. Troponin-I was elevated (534 ng/L, NR <0.04ng/ml) but proportionately much lower 
than the troponin T, suggesting some cardiac involvement (despite reassuring CMR).  
 
TREATMENT 
In the absence of any overt myocardial damage and following clinical improvement, the patient 
was discharged from the acute cardiology ward with urgent outpatient Rheumatology follow-up 
arranged (pending CK electrophoresis, troponin-I and autoimmune serology). At Rheumatology 
review two weeks following hospital-discharge, the patient was noted to be unwell with a cough 
and hypoxia. He was readmitted to hospital with suspected aspiration pneumonia.   
 
The patient’s autoimmune profile identified the presence of anti-Scl70 antibodies. No overt 
cutaneous features of connective-tissue disease were present. CK remained elevated at 6255 IU/L 
(normal range 30 – 200 IU/L in men) and the troponin-T rose to >9999 ng/L (normal range <15 
ng/L).  
 
A myositis-protocol MRI demonstrated abnormal increased signal intensity on STIR from the 
proximal thigh muscles, with no evidence of atrophy on T1, consistent with an acute myositis 
(Figure 4). The constellation of cardiac and skeletal muscle MR findings, together with positive anti-
Scl-70 antibodies, led to a diagnosis of fulminant Immune-Mediated Necrotizing Myopathy 
(IMNM). IMNM is characterised by proximal muscle weakness, grossly elevated muscle enzymes, 
autoantibodies and inflammatory change on muscle biopsy.[3]  In IMNM, in contrast to other 
inflammatory myopathies, myofibre necrosis is a prominent feature rather than the per-vascular 
lymphocytic infiltration typically identified on histological assessment of uncomplicated idiopathic 
inflammatory myopathy. Muscle prognosis is worse in IMNM and many patients have persistent 
weakness despite aggressive immunosuppressant treatment. [3] Cardiac involvement is a rare but 
important cause of morbidity in IMNM.  
 
Treatment was commenced with intravenous antibiotics and high dose intravenous corticosteroids; 
however, the patient continued to deteriorate and was transferred to higher acuity ward-based 
care, where treatment with intravenous immunoglobulin (IVIg) was commenced. Due to the rapid 
deterioration, a muscle biopsy was not possible.  
 
 
OUTCOME AND FOLLOW-UP 
The patient continued to deteriorate with Type 1 respiratory failure, requiring emergency 
intubation on the ward and he was transferred to the Intensive Care Unit. Treatment was 
continued with intravenous corticosteroids and antibiotics and intravenous immunoglobulin 
(IVIg) therapy. Several attempts to extubate were unsuccessful due to profound respiratory 
muscle weakness. Following a small improvement in clinical condition and successful extubation, 
the patient together with his family decided to cease active management. He was transferred 
home for best supportive care with palliative team input, where he subsequently died. 
 
DISCUSSION  
Our case illustrates the value of CMR and careful analysis of serum biochemistry in 
differentiating a suspected case of MINOCA from fulminant (IMNM. CMR has a leading role in 
the diagnosis of alternative causes of symptoms in patients with non-obstructed coronaries.[4] 
Non-infarction differential diagnoses of elevated troponin can be classified as either ‘coronary 
causes’, ‘non-coronary cardiac causes’ and ‘non-coronary non-cardiac causes’, and include 
pathology ranging from plaque rupture, myocarditis and pulmonary embolism.[5] A meta-
analysis of MINOCA patients demonstrated that, following CMR, cardiac myocarditis and an 
occult subendocardial infarct are the most common diagnoses.[1] 
 
In our case, chest pain and raised troponin-T was likely related to his shoulder girdle/chest wall 
skeletal myositis. Troponin-I is considered to be exclusive to myocardial tissue whereas 
troponin-T, the basis for high-sensitivity tests in our hospital, has been detected in healthy 
adults and regenerating adult skeletal muscle tissue.[6] Several studies have reported a close 
correlation with elevated troponin-T and CK; particularly CK-MB. This may be due to 
regenerating skeletal muscle tissue undergoing a phenotype switch where previously repressed 
cardiac troponin-T (along with CK-MB) is re-expressed in adult regenerating skeletal muscle 
tissue.[5] Persistently elevated serum troponin-T levels have also been diagnosed in patients 
with myositis where myocardial damage has been excluded.[7] Isotype analysis of serum CK and 
troponin in our patient demonstrated the elevations were predominantly secondary to skeletal 
muscle dysfunction, rather than cardiac. 
 
The presence of a pericardial effusion in our patient, although not specific for myocarditis, raises 
the possibility of active inflammation despite the absence of other features of myocarditis on 
CMR.[7] Myocardial LGE, which can be due to acutely damaged and/or chronically scarred 
myocardium, has been demonstrated to be less sensitive in milder cases, which may explain why 
there was no myocardial oedema or LGE in our patient.[8] 
 
CMR and serum biomarkers have an important role in the investigation of patients with a clinical 
diagnosis of myocardial infarction and non-obstructed coronary arteries. To our knowledge, this 
is the first reported case of shoulder girdle myositis secondary to IMNM mimicking MINOCA. Our 
case highlights the importance of careful review of CMR for extra-cardiac findings and the 
importance of further biochemical and rheumatological work-up of patients with suspected 
MINOCA and known/suspected autoimmune rheumatic disease.  
 
 
LEARNING POINTS/TAKE HOME MESSAGES  
• Troponin is a biomarker for myocardial damage. However, in addition to coronary 
causes, troponin levels can be elevated due to non-coronary cardiac causes and non-
cardiac causes. A high index of suspicion is required to differentiate common causes of 
MINOCA from rare mimics.  
 
• Troponin-T is released by regenerating skeletal muscles; such that levels can remain 
persistently raised in patients with myositis.  
 
• CMR has a leading role in differentiating the possible alternative causes of symptoms in 
patients with non-obstructed coronary arteries.  
 
• Careful review and identification of extra-cardiac findings on CMR is important: many 
cardiac diseases have systemic consequences and non-cardiac causes for presentation 
may be demonstrated.   
 
• In immune-mediated myopathy, cardiac involvement is a rare but important cause of 
morbidity. Patients with suspected MINOCA and known/suspected autoimmune 
rheumatic disease require early rheumatological input alongside imaging and 
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Figure 1. Admission ECG demonstrating left bundle branch block (QRS 140ms).  
 
Figure 2. Diagnostic coronary angiogram demonstrating with A) only mild atheroma of the left main 
stem, A) mild-moderate diffuse atheroma of the left anterior descending, B) unobstructed left circumflex 
and C) mild atheroma of the right coronary artery. 
 
Figure 3. Cardiac magnetic resonance images. T2-weighted Short Tau Inversion Recovery (T2-STIR) 
images of the A) cardiac short-axis basal, C) cardiac short-axis mid and C) cardiac short-axis apical 
segments demonstrating no increased signal return to suggest myocardial oedema and D) trans-axial T2- 
STIR image of the thorax demonstrating high signal return from the visualised left shoulder girdle muscles 
(latissimus dorsi and serratus anterior, arrowed). Late gadolinium enhancement (LGE) images of the E) 
cardiac short-axis basal, F) cardiac short-axis mid and G) cardiac short-axis apical segments 
demonstrating no enhancement and H) trans-axial LGE image of the thorax demonstrating patchy 
enhancement of the left shoulder girdle muscles (latissimus dorsi and serratus anterior, arrowed).  
 
Figure 4. Magnetic Resonance Images of the thigh: (a) coronal T1; (b) coronal STIR; (c) axial T1 and (d) 
axial T2, show oedema within the adductor compartments bilaterally (arrows) without substantial 




Unfortunately, the patient’s perspective could not be obtained as he sadly passed away.  
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